Provided by Tiger Trade Technology Pte. Ltd.

Mirum Pharmaceuticals, Inc.

103.10
+1.091.07%
Post-market: 103.100.00000.00%19:38 EST
Volume:682.82K
Turnover:70.29M
Market Cap:6.17B
PE:-122.84
High:103.70
Open:102.09
Low:100.83
Close:102.01
52wk High:105.74
52wk Low:36.88
Shares:59.88M
Float Shares:39.99M
Volume Ratio:1.36
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8393
EPS(LYR):-1.8505
ROE:-15.81%
ROA:-3.60%
PB:21.14
PE(LYR):-55.71

Loading ...

Mirum Pharmaceuticals Grants Stock Options and Equity Awards to New Employees

Reuters
·
Feb 11

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Feb 11

Mirum Pharmaceuticals Announces Health Canada Authorization of Livmarli® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients With Alagille Syndrome

THOMSON REUTERS
·
Feb 05

Health Canada genehmigt LIVMARLI von Mirum Pharmaceuticals zur Behandlung von cholestatischem Pruritus bei PFIC

Reuters
·
Feb 05

Mirum Pharmaceuticals Announces Health Canada Authorization of Livmarli® for the Treatment of Cholestatic Pruritus in Patients With Progressive Familial Intrahepatic Cholestasis (Pfic)

THOMSON REUTERS
·
Feb 05

Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jan 31

Mirum Pharmaceuticals Inc : TD Cowen Raises Target Price to $115 From $95

THOMSON REUTERS
·
Jan 29

Mirum Pharmaceuticals director buys $9.0M in common stock

TIPRANKS
·
Jan 28

Mirum Pharmaceuticals CEO Christopher Peetz Reports Disposal of Common Shares

Reuters
·
Jan 28

Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics

Reuters
·
Jan 26

Mirum Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 26

Mirum Pharmaceuticals Inc : Leerink Partners Raises Target Price to $105 From $100

THOMSON REUTERS
·
Jan 26

Mirum Pharmaceuticals price target raised to $130 from $102 at H.C. Wainwright

TIPRANKS
·
Jan 26

HBM Healthcare Investments Reports CHF 286 Million Profit for First Nine Months of 2025/2026

Reuters
·
Jan 23

Evercore ISI Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
Jan 20

Mirum Pharmaceuticals (MIRM) Is Up 5.2% After Issuing Confident 2026 Revenue Outlook and Pipeline Update

Simply Wall St.
·
Jan 19

A Look At Mirum Pharmaceuticals (MIRM) Valuation After Strong Recent Share Price Momentum

Simply Wall St.
·
Jan 18

Director Saira Ramasastry Reports Disposal of Mirum Pharmaceuticals Common Shares

Reuters
·
Jan 17

Mirum Pharmaceuticals Price Target Raised to $102.00/Share From $81.00 by HC Wainwright & Co.

Dow Jones
·
Jan 13

Mirum Pharmaceuticals price target raised to $102 from $81 at H.C. Wainwright

TIPRANKS
·
Jan 13